SCHEMBL4510686

SCHEMBL4510686

CN1CCN(Cc2nc(-c3ccccc3F)oc2C(=O)O)CC1

nearest known ligand 0.52

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.52
TSHR P16473 6/20 0.51
LMNA P02545 5/20 0.51
SMN1; SMN2 Q16637 4/20 0.51
MAPK1 P28482 3/20 0.51
ALDH1A1 P00352 4/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
NPSR1 Q6W5P4 1/20 0.47
TP53 P04637 2/20 0.45
POLB P06746 2/20 0.45
MAPT P10636 3/20 0.43
HTT P42858 1/20 0.43
MEN1 O00255 2/20 0.43
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4493273 0.88 TSHR (0.51) KMT2ATSHRLMNASMN1; SMN2MAPK1
SCHEMBL4504143 0.78 KMT2A (0.52) KMT2ATSHRLMNASMN1; SMN2MAPK1
SCHEMBL4485984 0.77 SMN1; SMN2 (0.46) KMT2ATSHRLMNASMN1; SMN2ALDH1A1
SCHEMBL4489532 0.74 SMN1; SMN2 (0.46) KMT2ATSHRLMNASMN1; SMN2ALDH1A1
SCHEMBL4498797 0.74 TSHR (0.46) KMT2ATSHRLMNASMN1; SMN2MAPK1
SCHEMBL25761573 0.72 ALDH1A1 (0.65) KMT2ATSHRLMNASMN1; SMN2MAPK1
SCHEMBL27738187 0.71 NPC1 (0.41) KMT2ATSHRLMNASMN1; SMN2ALDH1A1
SCHEMBL4762442 0.69
SCHEMBL4488806 0.69 MAOA (0.50) KMT2ASMN1; SMN2MAPK1ALDH1A1L3MBTL1
SCHEMBL27738189 0.68 NPC1 (0.43) KMT2ASMN1; SMN2ALDH1A1TP53POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1917262-B1 PIPERIDINE AND PIPERAZINE DERIVATIVES AS P2X3 ANTAGONISTS HOFFMANN LA ROCHE (CH) 2011-12-14 EP disclosed
US-7491821-B2 2-(4-fluorophenyl)-4-propyl-oxazole-5-carboxylic acid {2-[4-(6-aminopyridin-2-yl)-piperazin-1-yl]-1-methyl-ethyl}amide; purinergic receptor antagonists, analgesics; urogenital, gastointestinal and respiratory system disorders ROCHE PALO ALTO LLC (US) 2009-02-17 US disclosed
CN-101282972-A Piperidine and piperazine derivatives as P2X3 antagonists HOFFMANN LA ROCHE (CH) 2008-10-08 CN disclosed
US-20070037974-A1 Inhibitors of P2X3 ROCHE PALO ALTO LLC 2007-02-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070037974-A1 Inhibitors of P2X3 P2RX3, P2RX4, P2RX5 KMT2A 1216/4885TSHR 799/4885LMNA 3865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.